RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CANbridge Pharma of Beijing and WuXi Biologics announced a strategic partnership to develop new treatments for rare diseases. The partnership combines WuXi Biologics’ discovery, development and manufacturing capabilities with CANbridge’s expertise in clinical development of orphan drugs. CANbridge expects to file the first China rare disease INDapplication from the partnership in 2019. WuXi Biologics will receive upfront payments, plus potential milestones and royalties on global sales for the partnership’s programs.
Source: China Biotoday
